Connor, Clark & Lunn Investment Management »

Enliven Therapeutics shares owned by Connor, Clark & Lunn Investment Management

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Connor, Clark & Lunn Investment Management from 13F filings

Historical chart of Connor, Clark & Lunn Investment Management investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Connor, Clark & Lunn Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Connor, Clark & Lunn Investment Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $3.0M 195k 15.40
2025-09-30 $712k 35k 20.47

More positions owned by Connor, Clark & Lunn Investment Management

Rbc Cad (RY)
Agnico (AEM)
Shopify Cl A Sub Vtg Shs (SHOP)
Toronto Dominion Bk Ont Com New (TD)
Cibc Cad (CM)
NVIDIA Corporation (NVDA)
Bk Nova Cad (BNS)
Apple (AAPL)
Invesco Exch Traded Fd Tr Ii Purbta Msci Us (PBUS)
Microsoft Corporation (MSFT)
Tc Energy Corp (TRP)
Celestica (CLS)
Enbridge (ENB)
Amazon (AMZN)
Barrick Mng Corp Com Shs (B)

View all positions for Connor, Clark & Lunn Investment Management

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Vestal Point Capital
Fairmount Funds Management
BlackRock
Polar Capital Holdings
VR Adviser
Vanguard Group
Henderson Group
Point72 Asset Management
Novo A/S
Blackstone Group
Capital Research Global Investors
Pictet Asset Management Holding SA

View all funds holding Enliven Therapeutics